Purple Biotech Ltd (formerly Kitov Pharma Ltd) is an Israel-based clinical-stage company. The Company develops drugs and therapies designed to overcome tumor immune evasion and drug resistance and improve treatment outcomes for cancer patients. Main products of Purple Biotech Ltd include CM24, NT219 and the CAPTN-3 platform. CM24 is a monoclonal antibody that blocks CEACAM1, a protein involved in cancer progression, immune evasion and metastasis. NT219 is a small molecule dual inhibitor of IRS1/2 and STAT3, two cancer resistance pathways. CAPTN-3 is a preclinical platform of conditionally activated tri-specific antibodies designed to engage T cells and NK cells within the tumor microenvironment. The Company has also developed Consensi, a fixed-dose combination of celecoxib and amlodipine besylate for the simultaneous treatment of osteoarthritis pain and hypertension.
Back to dashboard
Company Information
About this company
Key people
Eric K. Rowinsky
Chairman of the Board
Robert E. Gagnon
Director
Itzhak Israel
Director
Suzana Nahum-Zilberberg
Director
Simcha Rock
Director
Shai Lankry
Chief Financial Officer
Gil Ben-Menachem
Vice President - Business Development
Avraham Ben-Tzvi
General Counsel, Secretary
Yisrael Gewirtz
Internal Auditor
Bertrand Liang
Chief Medical Officer
Hadas Reuveni
Founder and Chief Technology Officer of TyrNovo (a subsidiary)
Michael Schickler
Head of Clinical Operations
Gil Efron
Director
Click to see more
Key facts
- Shares in issue277,948.10
- EPICPPBT
- ISINUS74638P3073
- LocationIsrael
- SectorHealthcare
- IndustryBiotechnology & Drugs
- Market cap$10.12m
- Employees10
- ExchangeNASDAQ
- Index
- Website
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.